New bladder cancer strategy: targeted radiation or surgery after immunotherapy shows promise

NCT ID NCT07579195

Not yet recruiting Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This study is for people with advanced bladder cancer that has shrunk after initial treatment with two drugs (enfortumab vedotin and pembrolizumab). The goal is to see if adding focused radiation or surgery to remove remaining cancer can safely stop the disease from growing and allow patients to stop taking the drugs earlier, reducing side effects. The trial will enroll 12 adults and also use blood and urine tests to track cancer DNA.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV BLADDER CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MUSCLE-INVASIVE BLADDER CARCINOMA STAGE III BLADDER CANCER AJCC V8 STAGE IV BLADDER CANCER AJCC V8